© 2024 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
An oncologist writes about the valuable contributions of another oncologist in the field.
Dr. Antoinette J. Wozniak is a professor of medicine in the division of hematology/oncology at the University of Pittsburgh School of Medicine and associate director for clinical research and director of the lung cancer disease unit for the University of Pittsburgh Medical Center Hillman Cancer Center. Prior to this, she was a professor of oncology and leader of the multidisciplinary thoracic team at the Barbara Ann Karmanos Cancer Institute in Detroit, Michigan.
Dr. Wozniak has been an oncologist for more than 30 years. For 25-plus years, she has devoted her practice to the care and treatment of patients with lung cancer. Her main research interests have been in clinical trials for thoracic malignancies and new drug development. She has been a researcher for numerous clinical trials, including national trials conducted through the Southwest Oncology Group and at her own institution. She has more than 250 published articles, abstracts and book chapters. She is an active member and has served on several committees for the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. She has served as a member of the Oncology Drugs Advisory Committee for the Food and Drug Administration and is on the medical advisory board of the American Lung Association. She is editor in chief of Clinical Lung Cancer. She was a founding member of Free to Breathe, where she has served as secretary-treasurer and on the board of directors, and she has continued on the scientific committee since the organization’s merger with the Lung Cancer Research Foundation.
She is an active educator, team player, patient-centered physician and strong patient advocate. She is very worthy of this recognition as a lung cancer hero.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Related Content:
‘One Tree Hill’ Actor Dies of Cancer, ‘Jeopardy!’ Contestant Reveals Diagnosis and More
Magrolimab-Chemo Combo Improves Responses in Metastatic NSCLC
Subcutaneous Keytruda Plus Berahyaluronidase Alfa Combo Meets Phase 3 Trial End Points in NSCLC
UGN-102 Shows Promising Treatment Responses in Recurrent Bladder Cancer